Lowering c-Myc to treat aggressive large B‑cell lymphoma
Official title: Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma
Funded at Ohio State University · NIH-11321531 · Data updated 2026-11-12
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $570,593 |
| NIH project number | 5R01CA266682-05 |
| Project ID | NIH-11321531 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with aggressive diffuse large B‑cell lymphoma whose tumors show high c‑Myc expression (including double‑expressor, double‑hit, or triple‑hit cases) would be the likely candidates for future trials.
✕Less likely to help
Patients whose lymphomas do not overproduce c‑Myc or who have different cancer types are unlikely to benefit from this specific approach.
What this research studies
Many aggressive large B‑cell lymphomas make too much of a cancer protein called c‑Myc, and those patients do worse with current treatments. The team is studying an adaptor protein called TBL1 and using a drug (tegavivint) and genetic approaches to make c‑Myc less stable in lymphoma cells. They will use laboratory models and preclinical experiments to see whether lowering c‑Myc slows tumor growth and makes other therapies work better. The goal is to turn those lab findings into new treatment options for patients whose tumors overexpress c‑Myc.
Why it matters
Potential benefit: If successful, this could produce a new targeted treatment that improves outcomes for patients with c‑Myc overexpressing large B‑cell lymphoma.
How similar studies have gone: Preclinical work targeting TBL1 and c‑Myc has shown promise in lab models, but clinical proof in patients is still limited.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Alinari, Lapo — Ohio State University
- Study coordinator: Alinari, Lapo
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
EBV-related lymphoma in people with immune deficiency: understanding what drives the disease
A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.